Boston Stock Today

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>BS</div>
Boston Scientific is trading at 34.68 as of the 12th of July 2020; that is 0.52 percent increase since the beginning of the trading day. The stock's open price was 34.5. Boston Scientific has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 30 days. Equity ratings for Boston Scientific are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 13th of April 2020 and ending today, the 12th of July 2020. Click here to learn more.

   Performance
0 100 

   Odds of Distress
13  

Boston Scientific Profile

The upcoming quarterly report is expected on the 29th of July 2020. The stock is undervalued compared to its sector. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts. Boston Scientific operates under Medical Devices classification in the United States and is traded on BATS Exchange. It employs 36000 people. more on Boston Scientific
Boston Scientific Fama & French Medical Equipment
Medical Equipment
Fama & French Classification
Boston Scientific SEC Filings
Boston Scientific SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameBoston Scientific
Older SymbolBSX-PA
ChairmanMichael MahoneyView All
Thematic Classifications
Active investing themes Boston Scientific currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
showing 2 out of 3 themes  View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Boston Scientific. The Boston consensus assessment is calculated by taking the average estimates from all of the analysts covering Boston Scientific
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Boston Scientific financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 8 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.3 B1.4 B
Notably Down
Decreasing
Slightly volatile
Weighted Average Shares Diluted1.3 B1.4 B
Notably Down
Decreasing
Slightly volatile
Net Cash Flow from Operations1.6 B1.8 B
Fairly Down
Increasing
Stable
Total Assets28 B30.6 B
Significantly Down
Increasing
Slightly volatile
Total Liabilities15.6 B16.7 B
Significantly Down
Increasing
Slightly volatile
Current Assets4.6 B4.7 B
Fairly Down
Increasing
Slightly volatile
Current Liabilities4.4 B4.9 B
Significantly Down
Increasing
Slightly volatile
Total Debt8.5 B10 B
Fairly Down
Increasing
Slightly volatile
Return on Average Assets0.190.178
Notably Up
Increasing
Slightly volatile
Gross Margin0.770.71
Significantly Up
Increasing
Slightly volatile
Asset Turnover0.450.407
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Boston Scientific available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Cautious HoldUndervalued
Financial Strength
Boston Scientific financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Boston Scientific success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
BB+ ( Average Bond Rating ) Somewhat Erratic
  Operating Cash Flow
Boston Scientific (BSX) is traded on BATS Exchange in USA. It is located in 300 Boston Scientific Way, Marlborough, MA 01752-1234, United States and employs 36,000 people. Boston Scientific was also traded as Boston Scientific Corp on BATS Exchange under the symbol BSX-PA. Boston Scientific is listed under Medical Equipment category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with total capitalization of 49.29 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Boston Scientific's market, we take the total number of its shares issued and multiply it by Boston Scientific's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Boston Scientific runs under Healthcare sector within Medical Devices industry. The entity has 1.43 B outstanding shares of which 18.64 M shares are currently shorted by investors with about 1.5 days to cover shorted positions. BOSTON SCIENTIFIC has about 370 M in cash with 1.41 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.26.
Check Boston Scientific Probability Of Bankruptcy

Ownership Allocation (%)

Boston Stock Price Odds Analysis

Odds Down 34.68HorizonTargetOdds Up 34.68
25.95%30 days
 34.68 
73.87%
Based on a normal probability distribution, the odds of Boston Scientific to move above the current price in 30 days from now is about 73.87 (This Boston Scientific probability density function shows the probability of Boston Scientific Stock to fall within a particular range of prices over 30 days) .

Boston Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Nelson Van Denburg Campbell Wealth Management Group LlcCommon Shares8.1 K285 K
Modus Advisors LlcCommon Shares7.5 K263 K
View Boston Scientific Diagnostics

Boston Scientific Income Statement Over Time

Boston Scientific Income Statement is one of the three primary financial statements used for reporting Boston's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Boston Scientific revenue and expense. Boston Scientific Income Statement primarily focuses on the company's revenues and expenses during a particular period. Boston Scientific Consolidated Income is fairly stable at the moment as compared to the past year. Boston Scientific reported Consolidated Income of 4.7 Billion in 2019. Earning Before Interest and Taxes EBIT is likely to grow to about 1.3 B in 2020, whereas Direct Expenses is likely to drop slightly above 2.7 B in 2020. View More Fundamentals

Boston Stock Against Markets

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module

Boston Scientific Upcoming and Recent Events

Boston Scientific Company Earnings Announcements Dates

Upcoming Quarterly Report29th of July 2020
Next Earnings Report28th of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End3rd of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Boston Scientific Corporate Filings

Boston Scientific SEC Reporting

Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
Unclassified Corporate Event
View

Boston Scientific Corporate Directors

Edward Ludwig Lead Independent Director
Donna James Independent Director
Stephen MacMillan Independent Director
Continue to Trending Equities. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page